- Accesswire•yesterdayBiotech's Rally Shows No Signs of Slowing Down: Today's Reports on Eyegate Pharmaceuticals and VIVUS
NEW YORK, NY / ACCESSWIRE / February 22, 2017 / The Biotech Industry's rally does not appear to be losing any steam in 2016. Both the iShares NASDAQ Biotechnology Index ETF and the SPDR S&P Biotech ETF ...
- Zacks•last month
VIVUS, Inc. (VVUS) acquired exclusive global rights to develop and commercialize pulmonary arterial hypertension (PAH) drugs, tacrolimus and ascomycin from private biotech company, Selten Pharma, Inc.
VVUS : Summary for VIVUS, Inc. - Yahoo Finance
VIVUS, Inc. (VVUS)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||1.15 x 7800|
|Ask||1.16 x 3900|
|Day's Range||1.11 - 1.18|
|52 Week Range||0.93 - 1.85|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-2.64|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|